rtPA Infusion Dose Calculator icône

1.0 by Ho Hsuhua


Mar 1, 2016

À propos de rtPA Infusion Dose Calculator

Enjoy millions of the latest Android apps, games, music, movies, TV, books, magazines & more. Anytime, anywhere, across your devices.

Recombinant tissue plasminogen activator (rt-PA) was approved by the FDA in 1996 for the treatment of acute ischemic stroke. Despite its proven efficacy, however, rt-PA therapy has not been widely used among ischemic stroke patients. Studies have estimated that only 1.8% to 3.0% of all ischemic stroke patients in the United States are treated with rt-PA; the upper end of that range was not achieved until FY 2007. There are many reasons why rt-PA is not administered to more stroke patients, the most important of which is prehospital delays in presentation. Within the US population, only 8% of ischemic stroke patients present to an emergency department eligible for rt-PA. In addition, several important systems issues regarding the hospital of presentation affect whether a patient receives rt-PA, such as protocols for acute stroke patient triaging, stroke education for local EMS and ED staff, and 24-hour CT availability.

Quoi de neuf dans la dernière version 1.0

Last updated on Mar 1, 2016

Minor bug fixes and improvements. Install or update to the newest version to check it out!

Chargement de la traduction...

Informations Application supplémentaires

Dernière version

Demande rtPA Infusion Dose Calculator mise à jour 1.0

Telechargé par

Ronald Foston

Nécessite Android

Android 2.3.4+

Voir plus

rtPA Infusion Dose Calculator Captures d'écran

Charegement du commentaire...
Recherche en cours...
Abonnez-vous à APKPure
Soyez le premier à avoir accès à la sortie précoce, aux nouvelles et aux guides des meilleurs jeux et applications Android.
Non merci
S'inscrire
Abonné avec succès!
Vous êtes maintenant souscrit à APKPure.
Abonnez-vous à APKPure
Soyez le premier à avoir accès à la sortie précoce, aux nouvelles et aux guides des meilleurs jeux et applications Android.
Non merci
S'inscrire
Succès!
Vous êtes maintenant souscrit à notre newsletter.